Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?

Zoetis (ZTS) shares have increased by 8.1% since its last earnings report, outperforming the S&P 500, though estimates have trended downward over the past month. Zoetis currently holds a Zacks Rank #2 (Buy), suggesting an expected above-average return in the coming months, while competitor Recursion Pharmaceuticals (RXRX) has gained 17.2% over the past month and holds a Zacks Rank #3 (Hold).

Analysis

Zoetis (ZTS) shares have demonstrated notable strength, rising 8.1% since its last earnings report approximately a month ago, thereby outperforming the S&P 500. While analyst estimate revisions have trended downward for Zoetis over the past month, the article uniquely notes the 'magnitude of these revisions looks promising,' which, alongside a Zacks Rank #2 (Buy), suggests an expectation for above-average returns in the coming months. Zoetis exhibits a solid Growth Score of B but is assessed with C grades for both Momentum and Value, contributing to an overall aggregate VGM Score of B. In comparison, industry peer Recursion Pharmaceuticals (RXRX) has experienced a more substantial share price increase of 17.2% over the past month. Recursion Pharmaceuticals reported revenues of $14.74 million for the quarter ended March 2025, representing a 6.9% year-over-year increase, although its EPS of -$0.50 for the same period was wider than the -$0.39 reported a year ago. Looking ahead, Recursion Pharmaceuticals is expected to post a loss of $0.36 per share for the current quarter, which would be a 10% improvement year-over-year, and its Zacks Consensus Estimate has seen a positive change of +7.8% over the last 30 days, leading to a Zacks Rank #3 (Hold) and a VGM Score of F.

Key Decisions for Investors

• Investors considering Zoetis (ZTS) should acknowledge its recent 8.1% share appreciation and Zacks #2 (Buy) rating, but remain watchful of the downward trend in earnings estimates, despite their reportedly 'promising' magnitude, and how these reconcile with its B-grade Growth but C-grade Momentum and Value scores.
• The upcoming earnings release for Zoetis will be a critical data point to either validate the positive market sentiment reflected in its share performance and Buy rating or to indicate pressure from the recent downward estimate revisions.
• For Recursion Pharmaceuticals (RXRX), the significant 17.2% recent stock gain and improving loss-per-share outlook may attract speculative interest, but this should be carefully weighed against its current unprofitability, a neutral Zacks #3 (Hold) rating, and a notably weak VGM Score of F.